PMID- 17080020
OWN - NLM
STAT- MEDLINE
DCOM- 20070111
LR  - 20100115
IS  - 1812-9269 (Print)
IS  - 1812-9269 (Linking)
VI  - 28
IP  - 3
DP  - 2006 Sep
TI  - Leptin and resistin levels in serum of patients with hematologic malignancies: 
      correlation with clinical characteristics.
PG  - 241-4
AB  - AIM: To evaluate leptin and resistin levels in patients with various hematologic 
      malignancies. METHODS: We included 21 patients with lymphoma, 14 with multiple 
      myeloma (MM), 14 with acute leukemia, 13 with chronic lymphocytic leukemia (CLL), 
      and 25 healthy control subjects into our study. The subjects' body mass indexes 
      (BMI) were calculated; hematological and acute phase response parameters, serum 
      lipid were determined; serum leptin and resistin levels were determined by ELISA. 
      RESULTS: Serum leptin level was significantly increased in CLL and MM groups when 
      compared to the control group (p less, similar 0.01). Resistin level was 
      significantly higher in lymphoma patients than in CLL, acute leukemia and control 
      groups (p less, similar 0.01). In the control group, leptin level was negatively 
      correlated with hemoglobin level (r = -0.44, p = 0.047); and in all patients with 
      hematologic malignancies, leptin level was correlated with BMI (r = 0.32, p = 
      0.02). Leptin in lymphoma subjects correlated with hemoglobin level (r = 0.64, p 
      = 0.005), resistin level correlated with the platelet count in patients with 
      hematologic malignancies (r = 0.26, p = 0.044). In addition, leptin level had 
      negative correlations with international prognostic score (IPS) in Hodgkin 
      lymphoma (r = -0.9, p = 0.002) and with international prognostic index (IPI) in 
      non-Hodgkin lymphoma (r = -0.77, p = 0.03). In CLL patients, leptin level had a 
      correlation with the poor prognostic marker - CD38 level (r = 0.68, p = 0.03). 
      CONCLUSION: We found higher leptin levels in MM and CLL patients, and higher 
      resistin levels in lymphoma patients: this fact demonstrates that changes in 
      adipose tissue and metabolism occur in these disease states.
FAU - Pamuk, G E
AU  - Pamuk GE
AD  - Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey. 
      gepamuk@yahoo.com
FAU - Demir, M
AU  - Demir M
FAU - Harmandar, F
AU  - Harmandar F
FAU - Yesil, Y
AU  - Yesil Y
FAU - Turgut, B
AU  - Turgut B
FAU - Vural, O
AU  - Vural O
LA  - eng
PT  - Journal Article
PL  - Ukraine
TA  - Exp Oncol
JT  - Experimental oncology
JID - 101230541
RN  - 0 (Leptin)
RN  - 0 (Resistin)
SB  - IM
MH  - Adipose Tissue/metabolism
MH  - Adult
MH  - Aged
MH  - Female
MH  - Hematologic Neoplasms/*metabolism
MH  - Humans
MH  - Leptin/*blood/metabolism
MH  - Lipid Metabolism
MH  - Male
MH  - Middle Aged
MH  - Resistin/*blood/metabolism
EDAT- 2006/11/03 09:00
MHDA- 2007/01/12 09:00
CRDT- 2006/11/03 09:00
PHST- 2006/11/03 09:00 [pubmed]
PHST- 2007/01/12 09:00 [medline]
PHST- 2006/11/03 09:00 [entrez]
AID - 28/534 [pii]
PST - ppublish
SO  - Exp Oncol. 2006 Sep;28(3):241-4.